Prostate Cancer is Pandemic (World Wide) While the Rate of Failure is Epidemic!
PATIENT SELECTION PREDICTS EXCELLENT PROSTATE CANCER TREATMENT
SARASOTA, Fla., Nov. 4, 2014 /PRNewswire/ -- Is patient selection the key to successful prostate cancer treatment? In a study presented at the Western Section of the American Urological Association meeting on October 26, 2014, Dr. Ronald E. Wheeler, M.D. offered data indicating that high rates of cure for Prostate Cancer can be achievable using multi-parametric MRI diagnostic procedures. Cure rates in excess of 95% are now not only possible, but expected, with an improved diagnostic assessment. "Using 3.0 Tesla MP-MRI scans of the prostate and pelvic region allows us the ability to localize the cancer with great precision, thereby enabling a very targeted and successful treatment," Dr. Wheeler said. The essence of his poster presentation at the conference (shown below) represents a global comparison of the world's most prolific and leading treating Urologists using High Intensity Focused Ultrasound ("HIFU"). While the outcome data varies significantly among the world's experts, the 'game changer' in prostate cancer treatment is the use of the MP-MRI scan.
For more information on the study, or to speak directly to Dr. Wheeler, please contact his staff at the Diagnostic Center for Disease in Sarasota, Florida at 1-941-957-0007. (www.PanAmHIFU.com)
Below is a comparison of HIFU Experts from around the world with an assessment of their experience while treating a minimum of 67 patients with biopsy proven prostate cancer. All patients reported on had a single treatment with varying degrees of adverse events. These results were compared to the CaPSURE Data base as related to treatment success with either Radical Prostatectomy or Radiation therapy.
| Research Authors |
Country |
Treatment Modality |
BDFR (minimum of 34 mo.) |
| Blana, A., et al. |
Germany (2008) |
Ablatherm™ |
77% of patients with Low and Intermediate grade prostate cancers were cured at 5 years. In effect, 23% of patients were not cured. At 7 years his BDFR was 69% translating to 31% of patients not cured. |
| Blana, A., et al. |
Germany (2009) |
Ablatherm™ |
75% of Low grade and Intermediate prostate cancers were cured. In effect, 25% of prostate cancer patients were not cured. |
| Orovan, W., et al. |
Canada (2012) |
Ablatherm™ |
76% for Low grade prostate cancers and 69.5 % for Intermediate prostate cancers were cured at 4 years. In effect, 24% of Low grade cancers were not cured while 30.5% of Intermediate grade cancers were not cured. |
| Crouzet, S., et al. |
France (2010) |
Ablatherm™ |
83% for Low grade prostate cancers and 75% for Intermediate grade cancers. In effect, 17% of patients with a Low grade cancer were not cured while 25% of Intermediate grade cancers were not cured. |
| Uchida, T., et al. |
Japan (2008) |
Sonablate™ |
84% of Low grade prostate cancers and 64% of Intermediate grade prostate cancers were cured. In effect, 16% of patients with a Low grade cancer and 36% of Intermediate grade cancers were not cured. |
| Wheeler, R., et al. |
USA (2014) |
Ablatherm™ and |
97% of Low grade prostate cancers, 100% of Intermediate prostate cancers and 100% of High grade prostate cancers were cured at more than 7 years. In effect, only 3% of Low grade prostate cancers and no patients with Intermediate or High grade cancer failed to be cured. |
Agarwal, P., et al. CaPSURE Data (USA-2008) EBRT and Radical Surgery - 34% of all patients at any grade of prostate cancer were cured with Radiation while 77% of patients treated with Radical Prostatectomy were cured at 8 years. In effect, 66% of patients receiving Radiation failed to be cured while 23% of patients receiving Radical Prostatectomy failed to be cured.
Definitions: 1. Low grade prostate cancer is generally recognized as a Gleason score (GS) of 6 while Intermediate grade prostate cancer would be either a GS of 3+4=7 or 4+3=7. High grade prostate cancer is a 4+4=8, 4+5=9, 5+4=9 or a 5+5=10.
2. EBRT – External Beam Radiation Therapy
3. Ablatherm and Sonablate represent 2 technologies used in the HIFU treatment. Ablatherm™ is a robotic version of HIFU while the Sonablate™ technology is not.
4. BDFR stands for biochemical disease free rate or the ability to suppress the Prostate Specific Antigen (PSA) to a nadir or low point described by various authors to define success from a treatment modality.
CONTACT: John Frye, 1-941-957-0007, [email protected]
SOURCE Diagnostic Center for Disease
Share this article